The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.
|Slideshows|November 30, 2016
Top Lung Cancer News of 2016
Author(s)Cancer Network Editors
In this slide show we highlight some of the top news on lung cancer in 2016, including an immunotherapy approval from the FDA, and studies on depression in lung cancer patients, serious side effects to watch for when using immunotherapies, and more.
Advertisement
Advertisement
Related to this article
Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.
Advertisement
Advertisement
Trending on CancerNetwork
1
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
2
Operationalizing the First Dose and Building the Oncology and Eye Care Partnership
3
Reading a Changed Eye Examination and Impact on Therapy
4
Personalized Cancer Vaccine Combo Is Feasible in Platinum-Sensitive Ovarian Cancer
5